Sunshine Biopharma Reports 78% Revenue Growth and Key Developments in 2022

Sunshine Biopharma ( (SBFM) ) has issued an update.

Sunshine Biopharma reported a significant revenue increase of 78% in 2022, reaching $5.2 million. The company completed a public offering to expand sales operations and launched 14 new generic drugs. It received regulatory approval from Health Canada for its oncology drug, NIPEGS™, and published groundbreaking research on its coronavirus PLpro inhibitor. Additionally, the company completed mouse model studies for its mRNA Lipid Nanoparticle as a novel therapeutic agent for liver cancer, marking important milestones in its drug development program.

More about Sunshine Biopharma

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines across various therapeutic areas, including oncology and antivirals. The company currently markets 23 generic prescription drugs in Canada and plans to launch 16 additional drugs in 2023, including a biosimilar of NEULASTA®.

YTD Price Performance: -33.55%

Average Trading Volume: 86,191

Technical Sentiment Signal: Strong Buy

Current Market Cap: $5.17M

Find detailed analytics on SBFM stock on TipRanks’ Stock Analysis page.